Type of Spiritual Experience
A description of the experience
Saxagliptin , previously identified as BMS-477118, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed
In 4148 patients studied, 3 adverse reactions were seen higher in saxagliptin vs placebo.
1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5 mg and More Commonly than in Patients Treated with Placebo
|ONGLYZA 5 mg N=882||Placebo N=799|
|Upper respiratory tract infection||68 (7.7)||61 (7.6)|
|Urinary tract infection||60 (6.8)||49 (6.1)|
|Headache||57 (6.5)||47 (5.9|
On Dec, 30, 2016 4,803 people reported to have side effects when taking Onglyza.
Among them, 13 people (0.27%) have Hallucination
Time on Onglyza when people have Hallucination :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Gender of people who have Hallucination when taking Onglyza :
On Jan, 12, 2016: 2,682 people reported to have side effects when taking Onglyza. Among them, 28 people (1.04%) have Death.